Classification of germline variants identified in cancer predisposition genetic testing - consensus of the CZECANCA consortium.
Klasifikace zárodečných variant identifikovaných při genetickém vyšetření nádorové predispozice – konsenzus konzorcia CZECANCA.
clinical relevance
genetic testing
hereditary neoplastic syndromes
massively parallel sequencing
massively-parallel sequencing
national consensus
variant classification
Journal
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
ISSN: 1802-5307
Titre abrégé: Klin Onkol
Pays: Czech Republic
ID NLM: 9425213
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
29
12
2023
Statut:
ppublish
Résumé
Hereditary cancer syndromes are an important subset of malignant cancers caused by pathogenic variants in one of many known cancer predisposition genes. Diagnosis of cancer predisposition is based on genetic testing using next-generation sequencing. This allows many genes to be analysed at once, increasing the number of variants identified. The correct classification of the variants found is essential for the clinical interpretation of genetic test results. The aim of this study is to summarise the rules for classifying identified variants within individual laboratories and to present the process for creating a common classification. In the Czech Republic, the sharing of identified genetic variants and the development of their consensus classification among national laboratory diagnostic communities is carried out within the Czech Cancer Panel for Clinical Application (CZECANCA) consortium of scientific and diagnostic oncogenetic laboratories. Consensus for variant classification follows a defined protocol. Sharing the results and consensus classification accelerates and refines the release of genetic test results, harmonises results between laboratories and thus contributes to improving the care of individuals at high risk of cancer and their relatives.
Sections du résumé
BACKGROUND
BACKGROUND
Hereditary cancer syndromes are an important subset of malignant cancers caused by pathogenic variants in one of many known cancer predisposition genes. Diagnosis of cancer predisposition is based on genetic testing using next-generation sequencing. This allows many genes to be analysed at once, increasing the number of variants identified. The correct classification of the variants found is essential for the clinical interpretation of genetic test results.
PURPOSE
OBJECTIVE
The aim of this study is to summarise the rules for classifying identified variants within individual laboratories and to present the process for creating a common classification. In the Czech Republic, the sharing of identified genetic variants and the development of their consensus classification among national laboratory diagnostic communities is carried out within the Czech Cancer Panel for Clinical Application (CZECANCA) consortium of scientific and diagnostic oncogenetic laboratories. Consensus for variant classification follows a defined protocol. Sharing the results and consensus classification accelerates and refines the release of genetic test results, harmonises results between laboratories and thus contributes to improving the care of individuals at high risk of cancer and their relatives.
Identifiants
pubmed: 38158231
pii: 136059
doi: 10.48095/ccko2023431
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM